Log in with your email address username.


[Comment] Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma

Treatments targeting either specific transcripts (eg, breakpoint cluster region protein-Abelson murine leukaemia viral oncogene homologue 1 tyrosine kinase oncoprotein [BCR-ABL1] targeted by tyrosine kinase inhibitors)1 or leukaemic cell surface antigens (eg, CD20 monoclonal antibodies [mAbs])2 could be major breakthroughs in the treatment of acute lymphoblastic leukaemia. Rituximab is a chimeric human–mouse mAb against CD20, with efficacy in several lymphoid malignancies. Assessment of the addition of rituximab to chemotherapy for acute lymphoblastic leukaemia has been based on positive data in high-grade non-Hodgkin lymphoma, which has shown that addition of rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone) chemotherapy (R-CHOP) improves overall survival by at least 20%.